Stockwinners Market Radar for March 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:45 EDT Aeglea BioTherapeutics CEO buys $281K in common stock - In a regulatory filing, Aeglea BioTherapeutics disclosed that its CEO Anthony Quinn bought 145K shares of common stock on March 11th for $280.9K.

19:31 EDT Faraday Future gets Nasdaq acceptance to regain listing - Faraday Future has accepted the Company's plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), which permits the continued listing of FF common stock and warrants on the Nasdaq Global Select Market. Nasdaq has granted the Company an extension until May 6, 2022 to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. The extension also covers the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

18:34 EDT Occidental Petroleum director Poladian sells 20,000 common shares - In a regulatory filing, Occidental director Avedick Baruyr Poladian disclosed the sale of 20,000 common shares of the company on March 11 at a price of $57.23 per share.

18:15 EDT Walmart exec McKenna sells 15,000 common shares - In a regulatory filing, Walmart executive vice president Judith McKenna disclosed the sale of 15,000 common shares of the company on March 11 at a price o $142.6648 per share.

17:52 EDT Hess Corp. COO sells $7.2M in common stock - In a regulatory filing, Hess Corp disclosed that its COO Gregory Hill sold 101.6K shares of common stock for $7.23M following option expiry on March 14th.

17:13 EDT Butterfly Network director Larry Robins buys $2.25M in common stock - In a regulatory filing, Butterfly Network disclosed that its director Larry Robins bought 500K shares of common stock on March 15th in a total transaction size of $2.25M.

17:02 EDT Catalyst Biosciences regains full rights to CB 2782-PEG - Catalyst Biosciences (CBIO) announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD, or dAMD. Under the terms of the agreement, Biogen (BII) has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.

16:45 EDT Herc Holdings to acquire Cloverdale Equipment Company - Herc Holdings announced that it has entered a purchase agreement to acquire Cloverdale Equipment Company. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the second quarter of 2022. Cloverdale is a full-service general equipment rental company comprising approximately 120 employees and four locations serving construction and industrial customers with core operations in the metropolitan areas of Detroit and Grand Rapids, MI; Cleveland, OH; and Pittsburgh, PA. Terms were not disclosed.

16:33 EDT CarParts.com CEO Lev Peker to step down, David Meniane to succeed - CarParts.com announced effective April 18, COO & CFO, David Meniane will transition to CEO and SVP of finance, Ryan Lockwood will become CFO. Lev Peker will step down as CEO and director, effective as of close of business on April 15, to pursue other business opportunities. The company has also appointed Meniane as a Class III director to fill the resulting vacancy from Peker's departure from the board.

16:31 EDT Iovance Biotherapeutics announces FDA allows IOV-4001 IND to proceed - Iovance Biotherapeutics announced that the FDA has allowed an investigational new drug application, or IND, to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.

16:28 EDT Shift acquires Fair's dealer listing marketplace tech, SoftBank provides funding - Shift (SFT) has entered a definitive agreement to acquire certain assets of Fair Technologies for a combination of cash and shares of Shift's Class A common stock. Concurrently, Shift entered into a commitment letter with SoftBank Group (SFTBY), whereby SoftBank Group has agreed to purchase senior unsecured notes due in 2025, which will be used to fund the acquisition. "Shift and Fair share the same goal: to simplify the used vehicle purchasing process and empower customers through the entire lifecycle of car ownership," said George Arison, Shift's Co-founder and CEO. "At Shift, we've long envisioned building a digital marketplace where both dealers and independent sellers can list their cars alongside Shift's owned inventory, offering customers access to a greater selection of owned and third-party vehicles for a test drive or direct purchase - with all transactions fulfilled through Shift's proprietary logistics network." The acquisition of Fair's team and technology is expected to result in notable product synergies and significantly advance Shift's technology roadmap...The closing of the Fair acquisition and the purchase of notes are each subject to customary closing conditions. The transactions are expected to close in the second quarter of 2022.

16:24 EDT Talis Biomedical reports manufacturing challenges amid 25% workforce reduction - Talis has not started its phased launch of the Talis One COVID-19 Test System due to challenges with manufacturing. The company has engaged in a manufacturing review process to determine appropriate next steps and undertaken initiatives to align resources and preserve cash. Talis leadership has engaged in a manufacturing review process, with involvement from the board of directors, and external consultants, to assess product design for manufacturing at scale, evaluate current processes and partners, and to determine appropriate next steps and timing for bringing the Talis One system to market. The company is undertaking an approximately 25% reduction in workforce and implementing additional cost measures to align resources and extend cash runway. Doug Liu will be stepping down as COO and is transitioning his manufacturing and R&D responsibilities over the next several weeks.

16:19 EDT Spotify, FC Barcelona form long-term partnership - Spotify and Spanish soccer club FC Barcelona announced a long-term partnership, which officially kicks off in July 2022, where Spotify will become the Main Partner of the Club and the Official Audio Streaming Partner. "Our brand will appear on the front of both men's and women's team shirts and training shirts beginning in the 2022-2023 season," Spotify said. "Spotify and FC Barcelona will work together to create opportunities for the iconic shirt to be a space that celebrates artists from across the world. Spotify will also become Title Partner of the Stadium with the historic Camp Nou stadium rebranded Spotify Camp Nou." The partnership plans are subject to the ratification of the Barcelona Members Assembly, which will take place in early April. Reference Link

16:16 EDT IAA to continue 'constructive dialogue' with Ancora - IAA, Inc. issued the following statement regarding the letter it received from Ancora Advisors: "The IAA Board of Directors and management team are committed to enhancing value for our shareholders. IAA has built a differentiated platform with digital capabilities and strong customer relationships, and we are focused on driving growth and expanding our long-term profitability in a dynamic market environment. Our Board regularly evaluates our business and strategy, welcomes open communications with shareholders and is receptive to input that furthers the Company's goal of enhancing value for our shareholders. The Company looks forward to continuing a constructive dialogue with Ancora and the Board will continue to take actions that are in the best interests of the Company and all of its shareholders."

16:06 EDT Maxeon Solar announces 315MW order from Cypress Creek Renewables - Maxeon Solar Technologies announced that Cypress Creek Renewables, or CCR, placed a multi-year order for approximately 315 megawatts, or MW, of Maxeon's high-efficiency shingled bifacial Performance line solar modules. CCR has agreed to procure up to 315MW of Performance line modules to power multiple solar projects in both Washington and Texas. This new order follows an earlier purchase by CCR of 48MW of Maxeon's Performance line modules.

16:03 EDT Corporacion America Airport reports February traffic up 109% y/y - Corporacion America Airports reported a 109.0% y/y increase in passenger traffic in February 2022, reaching 65.0% of pre-pandemic levels of February 2019. When compared to February 2019, overall passenger traffic declined 35.0%, improving from the 37.0% decline posted in January. International and domestic passenger traffic improved sequentially reaching 51.9% and 74.0% of pre-pandemic levels of February 2019, respectively.

16:01 EDT Veritiv promotes Susan Salyer to General Counsel and Corporate Secretary - Veritiv announced that Susan Salyer, Veritiv's Senior Vice President and Chief Compliance and Sustainability Officer, will be promoted to General Counsel and Corporate Secretary, effective June 1. Salyer will succeed Mark Hianik, current Senior Vice President, General Counsel and Corporate Secretary, who announced plans to retire from Veritiv. In her expanded role, Salyer will be responsible for Veritiv's Legal and Corporate Security teams as well as her current Compliance and Sustainability oversight function. Susan joined Veritiv in 2012 and has held a variety of Legal and Compliance positions including Assistant General Counsel and Chief Compliance Officer. Salyer spearheaded Veritiv's 2020 Corporate Social Responsibility Report and led the establishment of the company's Sustainability Working Group. She is also responsible for leading Veritiv's Diversity, Equity and Inclusion initiative and serves as the Executive Sponsor for the Women's Employee Resource Group.

15:14 EDT Spartan Acquisition Corp. III, Allego expect to complete deal on March 16 - Spartan Acquisition Corp. III (SPAQ) announced that it plans to complete its business combination with Allego Holding B.V., a pan-European electric vehicle charging network, on Wednesday, March 16. In connection with the completion of the business combination, Allego N.V.'s ordinary shares and warrants are expected to commence trading on the New York Stock Exchange on Thursday, March 17, under the ticker symbols "ALLG" and "ALLG.WS," respectively. "We look forward to closing our business combination with Allego tomorrow and are very pleased to bring them public on the New York Stock Exchange to continue advancing EV charging across Europe," said Geoffrey Strong, Chairman and CEO of Spartan and Senior Partner and Co-Lead of Infrastructure and Natural Resources at Apollo. Spartan is sponsored by Spartan Acquisition Sponsor III LLC, which is owned by a private investment fund managed by an affiliate of Apollo Global Management (APO).

14:28 EDT Big Lots up 16% after Mill Road discloses 5% stake, pushes for sale - Shares of Big Lots are up $5.11, or 16%, to $37.10 in afternoon trading after Mill Road Capital disclosed a 5.1% stake in the company and urged it to "engage a financial advisor and pursue a sale process."

13:57 EDT Astra confirms successful deployment of satellites on Astra-1 mission - Astra tweeted: "We can confirm the successful deployment of the satellites on Spaceflight's Astra-1 mission today. We are grateful to our partner @SpaceflightInc and incredibly proud of this mission success." Reference Link

13:38 EDT Poet Technologies says critical development activities 'absorbed by Singapore' - Poet Technologies reported that as a response to the temporary lockdown resulting from a COVID-19 outbreak in Shenzhen, critical development activities have been absorbed by Singapore and other locations. "Over the past two years, we have established redundancy for critical activities in Singapore, Shenzhen and Allentown, Pennsylvania, both to accelerate development and to cope with COVID-19 lockdowns. On Sunday, March 13, 2022, our operation in Shenzhen, China was notified that it would be shut down until at least March 20, 2022, due to a COVID-19 outbreak in that city. We promptly tasked both Singapore and our joint venture, Super Photonics Xiamen, with the task of continuing to build samples for customers. Because we have been well-prepared for such a contingency, we do not believe this temporary lockdown will have any effect on our planned delivery schedule to customers, prospective customers or business partners," reported Dr. Suresh Venkatesan, CEO of Poet Technologies.

13:29 EDT EU unconditionally approves Amazon acquisition of MGM - The European Commission has approved unconditionally the proposed acquisition of MGM Holdings by Amazon.com. The Commission concluded that the transaction would raise no competition concerns in the European Economic Area. "Based on its market investigation, the Commission found that the transaction, as notified, would not significantly reduce competition in the markets for (i) the production and supply of AV content, (ii) the wholesale supply of TV channels, (iii) the retail supply of AV services, (iv) the production and licensing of distribution rights to third-party distributors of films for theatrical release and (v) the provision of marketplace services. These markets are found to be likely national in scope," the agency said in a statement,

12:31 EDT Xylem moving corporate headquarters to Washington, D.C. - Xylem announced that it will move its headquarters to Washington, D.C. Speaking about the relocation, Patrick Decker, president and CEO of Xylem, said, "Washington, D.C. is an important global crossroads for the diverse set of stakeholders who work together towards solving water challenges around the world. As a leading global water innovator, we know that the biggest water issues can only be addressed through collaboration. By locating our global headquarters here, we place ourselves right where the water sector is most engaged."

12:07 EDT American Express reports February net write-off rate 0.9% vs. 0.7% last month - Reports February 30 days past due loans as a percent of total U.S. Consumer Card Member loans 0.8% vs. 0.8% last month.

12:00 EDT PBF Energy falls -12.9% - PBF Energy is down -12.9%, or -$2.95 to $19.93.

12:00 EDT BP Prudhoe Bay falls -14.7% - BP Prudhoe Bay is down -14.7%, or -$1.51 to $8.76.

12:00 EDT Sonendo rises 17.1% - Sonendo is up 17.1%, or 58c to $3.98.

11:04 EDT Optibase sells three apartments, two penthouses in Florida for $8M - Optibase announced that between November 2021 and March 2022, the Company sold three apartments and two penthouses in Miami, Florida for a total consideration of approximately $8M. The consideration reflects an average price per square feet of $460 for the apartments and an average price per square feet of $990 for the penthouses. Following the last sale of the penthouse held on March 9, 2022, the Company fully repaid the loan granted as part of a financing agreement of the condominium units in Miami. The Company expects to record a combined gain on sale of operating properties in the Company's financial statements for the fourth quarter of 2021 and the first quarter of 2022 as a result of these sales in the amount of approximately $1.6M.

11:01 EDT Digital Ally's TicketSmarter, iHeartMedia enter multi-year agreement - Digital Ally (DGLY) announced that TicketSmarter and iHeartMedia (IHRT) have entered into a multi-year agreement that includes national marketing campaigns, prominent website feature displays and sponsorship of national contests. The national contests will be powered by TicketSmarter and allow iHeartRadio listeners the opportunity to win trips and experiences.

10:47 EDT American Airlines: Not much lag between restrictions lifting, demand coming back

10:45 EDT American Airlines CEO: Business travel coming back

10:39 EDT Dollar Tree receives grand jury subpoena over pests, sanitation - In a 10-K filing, Dollar Tree said, "On March 1, 2022, a federal grand jury subpoena was issued to us by the Eastern District of Arkansas requesting the production of information, documents and records pertaining to pests, sanitation and compliance with law regarding certain of our procedures and products. We intend to cooperate fully with the subpoena and any related investigation, however, no assurance can be given as to the timing or outcome of this matter."

10:26 EDT Meta fined EUR 17M by Ireland for 2018 data breaches - The Irish Data Protection Commission adopted a decision, imposing a fine of EUR 17M on Meta Platforms Ireland. The decision followed an inquiry by the DPC into a series of twelve data breach notifications it received in the six month period between June and December 2018. The DPC found that Meta "failed to have in place appropriate technical and organisational measures which would enable it to readily demonstrate the security measures that it implemented in practice to protect EU users' data, in the context of the twelve personal data breaches." Reference Link

10:05 EDT Cepton selected as exclusive lidar supplier of AutoDrive Challenge II - Cepton announced it has been selected as an official sponsor and exclusive lidar supplier for the prestigious AutoDrive Challenge II competition program. The AutoDrive Challenge II is a four-year STEM education program in which ten universities in North America each form a dedicated team of faculty members and students to develop an autonomous vehicle that can navigate urban driving courses as described by SAE Standard Level 4 automation. Through the extensive program syllabus and a series of challenges and competitions, participants will garner irreplaceable hands-on experience designing and developing AV systems, using a variety of technologies -- including sensors, computing platforms and software algorithms.

10:02 EDT Cushman & Wakefield promotes Sal Companieh to chief digital information officer - Cushman & Wakefield announced Sal Companieh has been promoted to Chief Digital & Information Officer, effective immediately. As Chief Digital & Information Officer, Companieh will report to Cushman & Wakefield's Chief Financial Officer Neil Johnston and will provide solutions that improve operations, enhance client service and drive new business. She will continue to be based in Boston. Companieh joined the company in 2011 as Vice President, Global Applications, and since that time has held technology leadership positions across the business, most recently as co-CIO.

10:01 EDT Taboola announces renewed partnership with Insider - Taboola announced a renewed partnership with Insider, the global news and lifestyle publisher owned by Berlin-based Axel Springer. "The new three-year deal marks a decade-long brand partnership in which Taboola has provided audience recommendations to readers and viewers of Insider. Since 2015, Insider has leveraged Taboola Feed, a seamlessly integrated tool that provides Insider's audience with personalized content and targeted advertisements that generate both audience engagement and revenue for Insider. Since the partnership began, Insider has seen double-digit growth in both engagement of recirculated content and revenue," the company stated. Adam Singolda, CEO at Taboola, added: "To play a part in Insider's continued growth, while also becoming their longest-standing partner in our space, is a testament to the mutual trust and benefits we've developed. Our focus on technology innovation and delivering real value to Insider has been key to forging our 10-year partnership. I look forward to continuing to grow together with Insider and its team."

10:00 EDT PBF Energy falls -8.4% - PBF Energy is down -8.4%, or -$1.93 to $20.95.

10:00 EDT Doximity rises 9.3% - Doximity is up 9.3%, or $3.78 to $44.63.

10:00 EDT Butterfly Network rises 9.6% - Butterfly Network is up 9.6%, or 36c to $4.10.

09:58 EDT SailingStone calls Rio Tinto bid for Turquoise Hill 'highly opportunistic' - SailingStone Capital Partners, a long-time owner of Turquoise Hill Resources (TRQ), has delivered a letter to the Turquoise Hill Independent Directors, which read, "We note with interest the recently announced cash bid from Rio Tinto (RIO) to acquire the minority stake in Turquoise Hill for C$34/share, or approximately $2.7bn. While we appreciate that a formal process has now commenced, we want to take this opportunity to highlight our perspective on the proposal. As you must know, Rio's cash cost basis in Turquoise Hill is approximately $6.6bn or $63.70 per share, inclusive of their participation in the January 2014 rights offering which was the last time that Rio acquired equity in TRQ. Other than a write down in 2013 related to the temporary closure of Oyu Tolgoi and again in 2019 related to their own incompetence, Rio has never impaired this asset. Given the billions of dollars of capex that subsequently has been deployed, the significant de-risking that has occurred, and the coming wall of free cash flow that begins with sustainable first production in 2023, we strongly suggest that any assessment of fair value starts with Rio's cash cost basis, particularly considering the impact that a much more robust commodity outlook and the time value of money have on TRQ's valuation. An additional premium to compensate minority shareholders for losing access to an asset of this quality seems eminently reasonable. On a related note, it is obvious that as the entity responsible for developing and operating the mine, Rio Tinto has access to a significant amount of material information which has yet to be released to the public. Specifically, TRQ management has indicated that updates to both the underground mine development plan and an open pit optimization are due in the next few months. Presumably neither the independent directors nor management has access to this information since it would have to be disclosed. And, presumably, the news can't be all that negative or Rio would not be making a cash bid, although we are concerned that Rio now is clearly conflicted in terms of providing fulsome updates to its partners and the market. Given the history of poor governance and repeated attempts at minority suppression, the structural asymmetry of information, and the bid that is on the table, how can you be confident that you are or will be informed sufficiently to determine a full and equitable purchase price?...This leads us to our final point: valuation. Rio is bidding $2.7bn to acquire the remaining 49.2% of TRQ that they don't own, compared to the $6.6bn spent to acquire 50.8% between 2006-2013. Even assuming much lower commodity prices than we are experiencing today, Turquoise Hill shareholders can reasonably expect a first dividend as early as 2025. Subsequently, free cash flow available for distribution ramps up to between $0.5-$4+bn per year, depending on your view of copper and gold prices. In other words, the bid represents less than a year of potential free cash flow... Rio's reminder in their proposal that 'should Turquoise Hill investors not accept the Proposed Transaction, Rio welcomes their continued investment and equal share of future risks and funding obligations' is laughable. TRQ minorities are the only investors with pure equity risk in this project and we have suffered from Rio's ineptitude along the way. Since Rio is convinced that 'the terms of the proposal are compelling for Turquoise Hill shareholders' surely the reverse is true as well. We would be more than happy to participate in a proposal to purchase Rio Tinto's stake in TRQ for C$34/share...In summary, this bid appears to be highly opportunistic, coming in the midst of an equity overhang caused by Rio's mismanagement of both the project and the partnership and just ahead of mine completion with the accompanying free cash flow that will benefit all stakeholders for decades into the future. Furthermore, the commodity backdrop is as attractive as it has ever been, placing a premium on any long-lived, low-cost reserve base. We expect that you will review all of your options and will undertake all steps necessary to ensure that Turquoise Hill's share price reflects its status as the owner of one of the most strategically important, structurally attractive assets in the world. We stand by, as always, to help in any way that we can.

09:49 EDT U.S. Gold provides update on assay results for drilling during 2021 field season - U.S. Gold is pleased to provide an update following receipt of assay results for a portion of the drilling conducted during the 2021 field season. The Company continues to be encouraged by the positive results confirming its prefeasibility study, released December 1, 2021. This drilling informs the engineering work aimed at developing the CK Gold Project. In commenting on this latest intercept, Kevin Francis, V.P. Exploration and Technical Services, of U.S. Gold Corp. said: "While we know that we have a high-grade zone starting at surface with minimal waste rock stripping required, we are encouraged by further evidence of higher grades than currently modeled. Hole CK21-01c drilled through the heart of the reserve was designed to intercept the proposed ultimate pit wall for geotechnical purposes. This area of the proposed pit is scheduled to be mined early in the mine life as outlined in the prefeasibility study, contributing to the very attractive production profile for the first three years of operation, averaging 135,300 gold equivalent ounces per year. While the hole pierced higher than average grades as estimated by the grade model, the actual grades intersected in CK21-01c are significantly higher. The grade block pierced by the 10-foot intercept of 11.8 g/t gold and 7.8% copper was estimated to contain 1.6 g/t gold and 0.3% copper. There is difficulty capturing extreme grades in a resource model due to geologic uncertainty at our nominal 150' drill hole spacing. We are unlikely to pursue changes in our resource and reserve estimate for the project, but we believe it lends confidence in our estimates. Historic mining at what was named Copper King in the 1920s also suggests that high-grade mineralization occurs because in those days constraints in technology made it simply uneconomic to mine the recently modelled average grade at the CK Gold Project. The project has significant leverage to rising metal prices and at recent $2,000/oz gold and $4.75/lb copper, the economics look extremely attractive. The deposit does not conveniently fit into one of the standard genetic models for gold and copper mineralization. With proven and probable reserves that currently stand at over 1 million ounces of gold and 248 million pounds of copper in a rising price environment, we believe that developing this U.S. domestic production will have widespread benefits. While we know that there are additional mineral resources both underlying and laterally contiguous to the modelled reserve, requiring further drilling definition, our focus is to realize the value of the commercially attractive gold-copper project identified in our prefeasibility study, published December 1, 2021."

09:47 EDT BP Prudhoe Bay falls -10.5% - BP Prudhoe Bay is down -10.5%, or -$1.08 to $9.19.

09:47 EDT Pearson rises 8.7% - Pearson is up 8.7%, or 87c to $10.90.

09:47 EDT Butterfly Network rises 9.8% - Butterfly Network is up 9.8%, or 36c to $4.11.

09:40 EDT Burning Rock Biotech secures second NGS Kit approval from NMPA - Burning Rock Biotech announced that the National Medical Products Administration approved Burning Rock's Human Nine-Gene Mutation Joint Detection Kit as a class III medical device. The company said, "This approval demonstrates Burning Rock's industry-leading capability of working with the NMPA on bringing an innovative next generation sequencing-based diagnostic product to the China market." LungCure CDx is the Company's second NMPA-approved NGS-based reagent kit for multiple gene mutation, following our industry-first kit approval in 2018. LungCure CDx can be used in in vitro detections of genetic variations of EGFR, ALK, ROS1, KRAS, MET, ERBB2, BRAF, PIK3CA and RET genes associated with non-small cell lung cancer patients, three of which are approved under the NMPA standards for companion diagnostics, and provide comprehensive guidance on NSCLC targeted therapy.

09:32 EDT Princess Cruises announces fleet deployment plans through April 2023 - Princess Cruises announced new deployment plans for the United States with a return to homeport cruising in Galveston, Texas starting in December 2022, and San Diego starting in September 2022. Princess is planning return to service in Australia with Coral Princess starting in June 2022 following indications authorities are becoming more comfortable with a return to service in the region. After six years, Princess returns to homeport cruising from Texas. Ruby Princess will sail from December 2022 to April 2023, on a series of cruises from Galveston ranging from five to 11 days, calling mainly to destinations in the Western Caribbean. The ship will also sail through the Panama Canal on two 16-day, ocean-to-ocean transits between Galveston and San Francisco. Cruises will be on sale April 7, 2022. From September 2022 through February 2023, cruising in California expands with a return to San Diego. Diamond Princess will be joining the fleet of west coast-based ships with a series of brand-new cruise itineraries ranging from five to 16 days and calling at ports along the Mexican Riviera, California Coast, and the Hawaiian Islands. In addition, the ship will sail a unique 20-day cruise to Central America, roundtrip from San Diego in November 2022. The on-sale date for these cruises is March 24, 2022. Royal Princess moves to San Francisco for the West Coast 2022/2023 season, with roundtrip cruises to Hawaii, Mexico, and the California Coast. Arriving in September 2022, after completing the Alaska season, Royal Princess will initially sail from San Francisco along with Ruby Princess. In December 2022, Ruby Princess relocates to Galveston and Royal Princess becomes the official hometown ship of San Francisco for the remainder of the 2022/2023 season. These cruises go on sale April 7, 2022. In anticipation that Australian Federal and State Governments will soon welcome the return of cruising, we are announcing plans for Coral Princess return to service in June 2022, with roundtrip Brisbane itineraries ranging from three- to 12-days in length and calling to destinations in Queensland and New South Wales. In August, Coral Princess will position to Sydney and depart on a new 12-day voyage calling to Queensland and the Conflict Islands in Papua New Guinea, before resuming the previously announced Australia & New Zealand program for the 2022/2023 season. Additionally, Majestic Princess will sail roundtrip from Sydney on a new Queensland voyage in February 2023 at the end of her already published season. Full details will be announced on March 17 and these Australia cruises will go on sale March 23, 2022. As a result of these changes, previously published itineraries through April 2023 on Diamond Princess, and Royal Princess to Japan, Singapore, Australia, New Zealand, and the South Pacific, as well as two Ruby Princess Panama Canal sailings in February 2023 and select voyages on Majestic Princess in Australia, New Zealand, and the South Pacific from February 2023 to May 2023 will be cancelled. Guests affected by these cancellations will be notified.

09:31 EDT Co-Diagnostics announces $30M share repurchase program - Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the company to repurchase up to $30M of CODX common stock.

09:22 EDT Altamira completes patient enrollment in house dust mite allergy trial - Altamira Therapeutics announced completion of patient enrollment in its Bentrio trial in house dust mite allergic rhinitis. The Company expects to release top-line results from the trial during the second quarter of 2022. The trial, which enrolled a total of 37 patients with a history of perennial allergic rhinitis caused by HDM exposure, is designed to evaluate the efficacy of Bentrio in the treatment of PAR in an environmental exposure chamber, i.e. under controlled HDM exposure. Study participants were randomized under an open label, three-period crossover design to receive either Bentrio in a single or double dose or no treatment prior to HDM exposure for three hours. The primary endpoint will be the change in the Total Nasal Symptom Score from baseline. The trial is being conducted at a single study site in Canada.

09:20 EDT Smart for Life executes definitive agreement to acquire Ceautamed Worldwide - Smart for Life announced that it has executed a definitive agreement to acquire Ceautamed Worldwide and its affiliates, Wellness Watchers Global and Greens First Female, a vitamin and supplement company principally engaged in the development and distribution of a wide variety of nutritional products. Ryan Benson will be staying onboard as the subsidiary Ceautamed's Chief Executive Officer post-acquisition. "This acquisition demonstrates Smart for Life's objective of creating a highly diversified vertically integrated global nutraceutical company. The Greens First brand is widely acknowledged as one of the best true greens powders on the market and fits nicely in our growing brand portfolio," stated Ryan Zackon, Smart for Life's Chief Executive Officer. "The transaction further supports Smart for Life's objective of developing and acquiring multiple brands and sales channels for cross marketing goods and services."

09:19 EDT Qualigen Therapeutics extends research agreement with ULRF - Qualigen Therapeutics announces the mutual extension of a research agreement with University of Louisville Research Foundation. The revised agreement expands the Company's collaboration with the research institution to develop its ongoing RAS-F platform currently in the discovery stage for solid tumors through Q1 of 2023. Mutant RAS is the most common cancer oncogene, present in one quarter of all cancers. It acts as a "hub" that activates multiple effector pathways to promote cancer growth. Targeting the downstream PI3K-AKT and RAF-MEK-ERK signaling pathways has been a promising therapeutic approach to date. However, approved therapeutic options are limited to cancers exhibiting specific RAS mutations, such as KRAS G12C. Exploring additional downstream effectors of the RAS pathway such as the RAL GTPase family are areas of active research as there are no FDA-approved pan-mutational RAS protein inhibitors. Qualigen's RAS-F program is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins. Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to inhibit a broad range of RAS mutations and are active against the growth of multiple in vivo tumor models. Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, colorectal and lung cancers.

09:18 EDT Hanmi Financial releases 2021 annual shareholder letter - Hanmi Financial announced the release of its 2021 annual letter to shareholders authored by President and Chief Executive Officer Bonnie Lee. "2021 Performance Highlights. Our team of 600 bankers performed exceptionally well in 2021 while continuing to navigate the challenges of the ongoing global pandemic, political and social volatility, and shifting economic dynamics. Guided by our strategic growth plan, we expanded our product and service offerings and diversified our loan and deposit portfolios. Working closely with our customers, we also further strengthened our portfolio and asset quality metrics... At the beginning of 2021, I outlined several strategic initiatives to grow and diversify our business, and I am pleased to report on our team's successful execution on these initiatives. We successfully ramped up production in our residential mortgage program, which accounted for 11 percent of originations in 2021, excluding PPP loans, in its first full year of operation... We advanced our Corporate Korea initiative, which accounted for more than 14 percent of our total 2021 loan production and 12 percent of total loans outstanding at year end... We expect this important program to make a growing contribution to both loan production and deposits in 2022 and beyond. These strategic growth initiatives, along with strong momentum across our diverse business lines, fueled record growth in loan and lease production in 2021... Our strategic priorities for 2022 include: Growing our successful residential mortgage business, Further diversifying our loan portfolios by building on the success of our Corporate Korea initiative as well as increasing multi-family and SBA loans, Increasing our focus more broadly on corporate clients to drive meaningful growth in loans and new sources of stable, low-cost deposits, Identifying strategic opportunities to enter new high-growth, deposit-rich verticals that need relationship banking partners like Hanmi...As we execute against a set of strategies that are paying off, we feel confident that 2022 will be another great year."

09:16 EDT Aware announces strategic partnership with MIRACL - Aware, announced it has entered into a partnership with MIRACL, a cybersecurity software company specializing in single-step, secure multi-factor authentication. Aware expects this partnership to enable it to extend its cloud-based biometric authentication technology to protect against data breaches and ransomware, which are continuing challenges in many industries, including financial services. This partnership further cements the value Aware is bringing to the financial services market, as demonstrated by its recent acquisition of Fortress Identity. Concurrently with entry into the partnership, Aware also made a $2.5 million strategic investment in loan stock issued by Omlis limited, the parent company of MIRACL.

09:13 EDT Verizon Business expands BlueJeans Telehealth - Verizon Business announced "enhanced access to new data sources and new partner integrations for BlueJeans Telehealth," the company said. Building on the platform's accessibility and ease-of use, the latest enhancements to BlueJeans Telehealth were designed to help improve the overall quality of virtual care. "Telehealth not only improves access to healthcare, it has the potential to improve the overall experience, especially for those who face real obstacles accessing specialized services," said Krish Ramakrishnan, Chief of Innovation and Product, BlueJeans by Verizon. "With our focus on simplified data integration, management and creating a seamless user experience, BlueJeans Telehealth is personalizing virtual care to make it easier, safer and more effective for patients and clinicians everywhere." With the latest data-driven enhancements and integrations built into the BlueJeans Telehealth solution, providers can pull televisit activity, give diagnostic intel and leverage more EHR platforms to improve healthcare insights. Key Features: Building on the existing integration, patients using an iPhone will be able to share additional categories of their Health app data in the coming months. The new Televisit tab included within BlueJeans' robust Command Center dashboard provides in-depth insights about telehealth activity. Redox is an EHR-agnostic interoperability platform that integrates with 85+ EHR systems, meaning providers can focus on using BlueJeans Telehealth to customize patient communication. BlueJeans Telehealth also includes new features, including Image Capture for patients and providers which enables either party to capture, upload and share images in the Televisit Tile during a televisit.

09:12 EDT Take-Two announces availability of 'Grand Theft Auto V' on latest consoles - Rockstar Games, a publishing label of Take-Two (TTWO), announced that "Grand Theft Auto V" and "GTA Online" are now available digitally for the PlayStation 5 (SNE) computer entertainment system and the Xbox Series S X (MSFT) games and entertainment system. Grand Theft Auto V and GTA Online are available together for $9.99 through the PlayStation Store and $19.99 through the Microsoft Store on Xbox through June 14, with physical releases coming in April. The new standalone version of GTA Online is also free to download now through the PlayStation Store through June 14.

09:11 EDT AMD announces availability of AMD Ryzen 7 5800X3D processor - AMD announced the pricing and availability of the AMD Ryzen 7 5800X3D processor.The AMD Ryzen 7 5800X3D processor is the first Ryzen processor to feature AMD 3D V-Cach technology. The 5800X3D delivers 15% more gaming performance compared to processors without stacked cache technology, making it the world's most advanced desktop gaming processor. AMD is also announcing a new stack of Ryzen 7, 5, and 3 Series processors and expanded chipset compatibility, giving PC enthusiasts even more options for creating truly customized gaming experiences. At CES 2022, AMD announced the Ryzen 7 5800X3D processor, an 8-core processor that is the first to feature AMD's 3D V-Cache technology, delivering the fastest 1080p gaming across select titles when compared to others in the market. AMD announced this new processor will be on-shelf globally beginning April 20, starting at an SEP of $449 USD.

09:09 EDT Intel to develop two fabs in Germany, double manufacturing space in Ireland - The investment program is centered around balancing the global semiconductor supply chain with a major expansion of Intel's (INTC) production capacities in Europe. In the initial phase, Intel plans to develop two semiconductor fabs in Magdeburg, Germany, the capital of Saxony-Anhalt. Planning will start immediately, with construction expected to begin in the first half of 2023 and production planned to come online in 2027, pending European Commission approval. The new fabs are expected to deliver chips using Intel's most advanced, Angstrom-era transistor technologies, serving the needs of both foundry customers and Intel for Europe and globally as part of the company's IDM 2.0 strategy. Intel plans to initially invest 17B euros, creating 7,000 construction jobs over the course of the build, 3,000 permanent high-tech jobs at Intel, and tens of thousands of additional jobs across suppliers and partners. Intel plans to refer to the new site as the Silicon Junction, connecting technology. This Silicon Junction will serve as the connection point for other centers of innovation and manufacturing across the country and region. Intel is also continuing to invest in its Leixlip, Ireland, expansion project, spending an additional 12B euros and doubling the manufacturing space to bring Intel 4 process technology to Europe and expand foundry services. Once complete, this expansion will bring Intel's total investment in Ireland to more than 30B euros. In addition, Intel and Italy have entered into negotiations to enable a back-end manufacturing facility. With a potential investment of up to 4.5B euros, this factory would create approximately 1,500 Intel jobs plus an additional 3,500 jobs across suppliers and partners, with operations to start between 2025 and 2027. Intel and Italy aim to make this facility a first of its kind in the EU with new and innovative technologies. This would be in addition to the foundry innovation and growth opportunities Intel expects to pursue in Italy based on its planned acquisition of Tower Semiconductor (TSEM). Tower has a partnership with STMicroelectronics (STM), which has a fab in Agrate Brianza, Italy. In total, Intel plans to spend more than 33B euros on these manufacturing investments. By significantly increasing its manufacturing capacities across the EU, Intel would lay the groundwork to bring various parts of the semiconductor value chain closer together and increase supply chain resiliency in Europe.

09:08 EDT RedHill Biopharma announces license agreement with Kukbo - RedHill Biopharma announced that it has entered into an exclusive license agreement with Kukbo, a South Korean corporation, for oral opaganib for the treatment of COVID-19, in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5M and is eligible for up to $5.6M in milestone payments as well as low double-digit royalties on net sales of oral opaganib in South Korea. Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19. The partnership with Kukbo also includes a right of first offer for RedHill's late-stage clinical assets, opaganib, RHB-107 and Talicia, for one or more of the territories of South Korea, Japan, Indonesia, Vietnam, Thailand and/or Malaysia. The right of first offer has been extended as part of the new license agreement until the end of October.

09:07 EDT Mile Auto integrates telematic solutions from Verisk Analytics - Mile Auto has integrated telematics solutions from Verisk to help consenting, low-mileage drivers easily access affordable car insurance based on how much they drive. By connecting to the Verisk Data Exchange and its network of automakers, Mile Auto will be able to deliver an efficient, customer-centric purchase experience to the growing number of connected car drivers.

09:06 EDT WISeKey says WISe.ART 2.1 NFT Marketplace fully operational - WISeKey International Holding announced that its new WISe.ART 2.1 NFT Marketplace version is fully operational and includes new features providing art collectors and artists a secure marketplace and platform where NFT buyers and sellers can easily connect their crypto wallets to instantly purchase or list their NFTs for sale.

09:05 EDT Amazon commits $124.4M for affordable homes in WA's Puget Sound, Arlington, VA - Amazon announced it will invest over $124.4M to build 1,060 affordable homes near four public transit sites and work in partnership with the Washington Metropolitan Area Transit Authority, Metro, and Sound Transit, the transit system serving the Central Puget Sound region of Washington state, to complete the housing developments. The new deals stem from Amazon's $300 million transit commitment from 2021 to create 3,000 new affordable homes in collaboration with the transit agencies in each region. The Margaux at the New Carrollton Metro station rendering "The Amazon Housing Equity Fund is tackling the affordable housing crisis on multiple fronts and through innovative solutions, such as teaming up with public transit authorities, which brings people closer to more opportunities, services, and a better quality of life," said Catherine Buell, director of the Amazon Housing Equity Fund, a more than $2 billion commitment to create and preserve 20,000 affordable homes for individuals and families earning moderate to low incomes in Washington state's Puget Sound region; the Arlington, Virginia region; and Nashville, Tennessee. "We know that our investment in these areas brings many economic opportunities for residents in the region, but we also acknowledge that this growth needs to benefit everyone in the community. The progress we have made in our first year is promising, but we have more to do."

09:03 EDT MongoDB expands global collaboration with AWS - MongoDB (MDB) announced a significant expansion of a multi-year strategic collaboration agreement with Amazon Web Services (AMZN). Under this six-year agreement, MongoDB and AWS have committed to a broad range of initiatives to make it easier for joint customers to advance their cloud adoption journey, including integrated go-to-market activities across sales and marketing, developer enablement and training through shared developer relations activities, and both technology integrations and commercial incentives to streamline the migration of on-premises workloads to MongoDB Atlas on AWS.

09:03 EDT Pushpay announces new product features to help churches re-engage - Pushpay announces new digital features within its giving solution, church management system, and mobile applications to help churches engage and increase involvement within their community. While the pandemic continues on, traditions of in-person gatherings are slowly showing signs of returning to normal, with roughly 21% of adults attending weekly religious services in-person-up from 5% in the spring of 2020*. Churches have relied heavily on technology to help them reach people during the last 24 months in particular, and there are no signs of that changing anytime soon as 93% recently indicated that technology plays an important role in helping them achieve their mission. Today the Company is hosting a product launch webinar at 11:30 a.m. PT to dive deeper into new Pushpay product features and explore how churches can leverage them to re-engage with people in their community. Key highlights include: App analytics: Provides a granular view of mobile app engagement and surfaces holistic trends on how community members are interacting with app content. Also delivers actionable insights to support churches as they lean into mobile engagement as a key part of their communication strategy. In fact, church leaders recently indicated that mobile church applications are one of the most strategically important technology tools for the future of their church. Event creation in-app: With in-person gatherings on the rise, group leaders now have the ability to quickly create events directly from their mobile church app and spark engagement with group members in real-time. Donor Development enhancements: Church leaders now have the flexibility to view gifts and engagement activity by individual or by household, and can toggle between views within the Donor Development dashboard. In addition, churches can now quickly view their top donors in a matter of seconds with a new report in the Donor Development dashboard. Draggable Resi livestream link: Enables churches that use Resi Media livestreaming technology the ability to easily add their Resi livestream and library videos to their Pushpay mobile application for a seamless viewing experience. Annual recurring giving: Community members now have the ability to set-up a recurring annual gift, for the date of their choice, which allows more flexibility as they actively seek to help their church, and or parish, grow. Spanish translation: Seamlessly translates localized content into Spanish within the LEAD mobile application, which also sets the foundation for expansion of translation in additional Pushpay products in the near future.

09:02 EDT JetBlue CEO: Q1 revenue outperforming original guidance range - Beyond the first quarter of 2022, JetBlue is moving swiftly to reduce May capacity by 6-8 percentage points, and expects to continue to moderate its capacity outlook into the Summer months, Hayes said.

09:01 EDT JetBlue sees Q1 revenue down 6%-9% vs. 2019 - Previous view was down 11%-16% vs. 2019. Sees Q1 ASMs down 1% vs. 2019 and previous view of down 1% to up 2%.

09:00 EDT Amazon $81.7M to build 742 new affordable near metro stations around D.C. - Amazon announced it will invest $81.7M to build 742 new affordable homes near public transit sites and work in collaboration with the Washington Metropolitan Area Transit Authority, Metro, to complete the housing developments. The deals stem from Amazon's $300M transit commitment from 2021 to create 3,000 new affordable homes in collaboration with the transit agencies in Amazon's hometown communities. authorities, which brings people closer to more opportunities, services, and a better quality of life," said Catherine Buell, director of the Amazon Housing Equity Fund, a more than $2 billion commitment to create and preserve 20,000 affordable homes for individuals and families earning moderate to low incomes in Washington state's Puget Sound region; the Arlington, Virginia region; and Nashville, Tennessee. "We know that our investment in these areas brings many economic opportunities for residents in the region, but we also acknowledge that this growth needs to benefit everyone in the community. The progress we have made in our first year is promising, but we have more to do."

08:57 EDT Amazon to invest over $42.5M to build affordable homes in Puget Sound region - Amazon announced it will invest more than $42.5M to build 318 affordable homes adjacent to public transit sites, and it will work in partnership with Sound Transit, the transit system serving the Central Puget Sound region of Washington state, to complete the housing developments. The deals stem from Amazon's $300M transit commitment from 2021 to create 3,000 new affordable homes in collaboration with the transit agencies in Amazon's three hometown communities of Washington state's Puget Sound region; the Arlington, Virginia region; and Nashville, Tennessee.

08:50 EDT Vicinity Motor expands U.S. distribution partnership with ABC Companies - Vicinity Motor announced the expansion of its strategic U.S. distribution agreement with ABC Companies, a provider of motorcoach and transit equipment in North America. The ABC distributorship supports Vicinity's focus on U.S. expansion to market the Vicinity heavy duty mid-size bus, the Vicinity Lightning EV and the VMC Optimal EV S1 low floor shuttle bus to new and existing customers. Under the expanded agreement, ABC will distribute Vicinity's product portfolio to 18 states covering key population centers across the country important to VMC's growth markets. The Vicinity line fills in key transit and private shuttle markets within the ABC portfolio of new vehicles for these locations, enhancing the offering to current customers while expanding to other sectors. In conjunction with the new agreement, ABC has contracted to order 18 VMC Optimal S1 shuttle buses and 3 Vicinity Classic buses - in addition to the previously announced order for 10 Vicinity Lightning EV buses slated for delivery in 2022.

08:48 EDT Innovation Pharmaceuticals announces publication of article on Brilacidin - Innovation Pharmaceuticals announced publication of a peer-review scientific article in the Journal of Medical Virology on the anti-coronavirus properties of Brilacidin. Brilacidin was shown to exert a dual-acting antiviral mechanism of action, able to target coronaviruses directly and bind to host cell surfaces to prevent viral entry. As previously released, Brilacidin showed promising treatment effects in a Phase 2 clinical trial in moderate-to-severe hospitalized cases of COVID-19. The Company plans to seek funding and additional clinical development support from government-sponsored programs to help advance the Brilacidin antiviral program. In the peer-review paper, which was co-authored by Dr. William DeGrado, University of Arizona and University of California-San Francisco scientists characterized the antiviral activity of Brilacidin against multiple endemic human coronaviruses, including HCoV-OC43, HCoV-229E, HCoV-NL63, and SARS-CoV-2, in human cell lines. Mechanistic studies revealed Brilacidin exerts antiviral activity by interfering with viral attachment to host cells by binding to heparan sulfate proteoglycans. HSPGs are important co-receptors through which different viruses gain entry into host cells, thus providing an attractive target for the development of broad-spectrum antivirals. Beyond exhibiting this blocking property, Brilacidin was also shown to target viral proteins directly, acting through a virucidal property. This dual antiviral mechanism of action suggests Brilacidin may be well-suited for prophylactic development and less likely to be subject to drug resistance. Combination studies further revealed Brilacidin exhibited a strong synergistic antiviral effect with remdesivir against HCoV-OC43 in cell culture. Collectively, these data support Brilacidin's translational potential to be developed as a broad-spectrum anti-coronavirus agent.

08:46 EDT Allegro MicroSystems unveils GMR crankshaft, camshaft sensors - Allegro MicroSystems announced the release of two new giant magnetoresistance crankshaft and camshaft sensors. The company said, "The ATS16951 and ATS16351 sensors are unique in the market and provide manufacturers with a single-vendor solution that's ideal for hybrid vehicle engines, with use cases extending to two-wheelers, off-road vehicles, and application designs requiring extended air gap performance. Both sensors will help engine designers reduce system complexity, cost, and energy consumption-boosting efficiency and minimizing carbon footprints."

08:42 EDT Quoin Pharmaceuticals announces submission of IND to FDA for QRX003 - Quoin Pharmaceuticals announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, has submitted an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, for QRX003, the Company's investigational product for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. QRX003 is a topical lotion, formulated with a proprietary delivery technology, and contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. "This is an important milestone for Quoin, and we'd like to thank everyone who participated in the preparation of the IND submission. We look forward to initiating clinical testing of QRX003 in this very underserved patient population," said Dr. Michael Myers, Chief Executive Officer of Quoin.

08:41 EDT David Hall proposes removal of Velodyne Lidar Chairman Michael Dee for cause - David and Marta Hall, former executive officers of and the beneficial owners of approximately 10.1% of the outstanding common stock of Velodyne Lida issued the below letter regarding their decision to submit a business proposal seeking the removal of Chairman Michael Dee for cause and nominate three candidates for election to the Company's Board of Directors at the 2022 Annual Meeting of Stockholders. The letter said in part: "We are the largest stockholders of Velodyne Lidar, with collective ownership of approximately 10.1% of the Company's outstanding common stock. As indicated in recent 13D filings, we sold shares of Velodyne Lidar common stock for liquidity purposes because we are limited in the amount of shares we can sell in open market purchases in any three month period. ..We are incredibly proud that lidar's 3D capabilities have forever transformed the autonomous industry in its application to promote safe navigation, mapping, robotics and city intersection management. The possibilities are truly endless with innovative lidar technology. Unfortunately, Velodyne Lidar finds itself at a challenging crossroads today. Over the past sixteen months, as the Company's stock price has declined nearly 90%, we have been deeply troubled by certain directors' anti-stockholder actions and have made it a point to raise these concerns publicly. We attribute this extreme loss in stockholder value, neglect of technology and complete disregard for sound corporate governance directly to a broken Board of Directors under the control of Chairman Michael Dee. We believe Mr. Dee has breached his fiduciary duties and is more focused on advancing his own self-serving agenda than helping save the Company, as evidenced by his changing director classes to avoid having to stand for re-election at this year's Annual Meeting of Stockholders. This entrenchment maneuver, as well as additional examples of concerning conduct below, is why we have put forth a business proposal to remove Mr. Dee from the Board for cause and decided to nominate three candidates for election to the Board at the 2022 Annual Meeting. We firmly believe that new directors can help realign the Board's priorities away from rewarding insiders and toward respecting stockholders."

08:41 EDT Allarity provides update on Dovitinib program - Allarity Therapeutics provided an update on its lead dovitinib program. On February 18, 2022, the Company announced that the U.S. Food and Drug Administration had provided the Company with Refusal to File, RTF, letters regarding the new drug application, NDA, for dovitinib, and its accompanying pre-market approval, PMA, application for the DRP-Dovitinib companion diagnostic, for the third-line treatment of metastatic renal cell carcinoma. Following several weeks of analysis by Company leadership together with clinical and regulatory experts, Allarity has now filed a formal request with the FDA for a "Type C" meeting to further discuss potential clinical paths to support approval of dovitinib, together with its DRP-Dovitinib companion diagnostic, in view of the FDA's recent RTFs. The Company anticipates providing a further update on the outcome of its FDA meeting and the future of the dovitinib program before the end of the third quarter of this year. "We look forward to working closely with the FDA and we remain highly confident in the clinical profile of dovitinib, together with the DRP(R)-Dovitinib companion diagnostic. We are determined to further advance this product candidate as a potential new treatment option for cancer patients," said Allarity's CEO Steve Carchedi. "With clarification from the FDA following our requested Type C meeting, we hope to have a clinical path forward with the goal of refiling our NDA and PMA once additional clinical data are in hand ."

08:39 EDT 5E Advanced Metals commences trading on Nasdaq - 5E Advanced Materials is pleased to announce that its' primary U.S. listing is now effective with the commencement of trading on the Nasdaq Global Select Market on March 15, 2022 under ticker symbol "FEAM." 5E's CHESS Depositary Interests will continue to trade on the Australian Securities Exchange under ticker symbol "5EA." Each FEAM share represents ten 5EA CDIs. In support of the Nasdaq listing, the Company has begun extensive investor outreach and non-deal marketing efforts in the U.S. with assistance from its capital markets advisor, BofA Securities.

08:37 EDT Wave Life Sciences to highlight RNA base editing modality, AATD program - Wave Life Sciences announced that it will highlight its therapeutic A-to-I RNA base editing oligonucleotides at two upcoming scientific and industry meetings. Preclinical data for Wave's Alpha-1 antitrypsin deficiency AIMer program, including editing efficiency, AAT protein restoration and reduction of liver aggregates with repeat AIMer dosing out to 19 weeks, will be shared in a Featured Session at the 7th Annual Oligonucleotide & Precision Therapeutics Congress, taking place March 15-16, 2022 in Boston, MA and virtually. The company's progress toward, and leadership in, advancing a therapeutic RNA base editing platform capability and pipeline will be highlighted in five sessions at the 3rd RNA Editing Summit, taking place April 5-7 in Boston, MA. AIMers are designed to correct single base mutations in an RNA transcript, thereby avoiding permanent changes to the genome that occur with DNA-targeting approaches. Rather than using an exogenous editing enzyme, AIMers recruit proteins that exist in the body, called ADAR enzymes, which naturally edit certain adenine bases to inosine, which cells read as guanine. This approach redirects a natural system for therapeutic purposes, relies on simplified delivery, and avoids the risk of irreversible off-target effects of DNA-targeting approaches. AIMers are short in length, fully chemically modified, and use novel chemistry, including proprietary PN backbone modifications and chiral control, that make them distinct from other ADAR-mediated editing approaches. Recently, data highlighting Wave's foundational AIMer technology were published in Nature Biotechnology.

08:35 EDT EarnUp closes $31M Series C funding round - EarnUp closed an oversubscribed $31 million Series C financing round. Included in this round are new strategic investors, LendingTree (TREE) and KeyBank (KEY), in addition to leading institutional investors, Bain Capital Ventures, SignalFire, Blumberg Capital, and Flourish Ventures. The company said, "With this latest round of funding, EarnUp will build on its mission to create a financial system that works for everyone by expanding its reinvention of payment and data flows for the mortgage industry that support borrowers, lenders, and servicers. The company's solutions reduce damaging delinquent and missed payments that harm credit scores and mortgage portfolios, and also streamline business operations in an effective, inclusive, and compassionate way."

08:34 EDT WisdomTree names ESG heads - WisdomTree Investments announced that Ben Wallach and Heather Reisner have been promoted to drive the firm's client-first ESG strategy in the U.S. Ben joined WisdomTree in 2011, focusing on product and business development for over a decade at the firm and is now Head of Product Development & ESG. Heather has been with WisdomTree since 2018 in a role overseeing the development of new products and management of existing products and is now Senior Associate, Product Development & ESG. WisdomTree, which offers three core integrated ESG ETFs in addition to ESG-screened funds and model portfolios as well as a suite of ex-state owned funds, ranks among the top 10 ESG ETF providers in the U.S. with assets in related funds totaling over $4 billion.

08:33 EDT Acco Brands names Deborah O'Connor CFO - ACCO Brands announced that Deborah A. O'Connor has been named as Executive Vice President and Chief Financial Officer, effective April 4. "Deb is an experienced Chief Financial Officer with a track record of delivering value with deep operational, industry, mergers and acquisitions, international and public company accounting experience. We're excited to have her join ACCO Brands and help lead our transformation to a faster growing brand-, consumer- and technology-centric company," said Boris Elisman, ACCO Brands Chairman and Chief Executive Officer.

08:32 EDT JPMorgan to acquire Global Shares, terms not disclosed - J.P. Morgan announced that it has entered into an agreement to acquire Global Shares, a cloud-based provider of share plan management software. Global Shares' employee ownership solutions cover the entire company lifecycle, and caters to corporates worldwide. The deal, the terms of which have not been disclosed, is subject to regulatory approvals and closing. The transaction is expected to close in the second half of 2022.

08:28 EDT Roblox reports February DAU 55.1M, up 28% - Roblox released certain key metrics for February. Daily active users were 55.1M, up 28% year over year. Hours engaged were 3.8B, up 21% year over year. Estimated bookings for February were between $203M and $206M, down 2%-4% year over year. Estimated average bookings per daily active user was between $3.68 and $3.74, down 24%-25% year over year. Revenue is estimated to be between $204M and $207M, up 60% - 63% year over year.

08:24 EDT Aemetis signs agreement with Qantas to supply 35M gallons of SAF - Aemetis announced that an offtake agreement has been signed with Qantas Group and Qantas Airlines for 35M gallons of blended sustainable aviation fuel, SAF, to be delivered over the 7 year term of the agreement. The value of the contract including incentives is approximately $250M. The sustainable aviation fuel is expected to be produced by the Aemetis renewable jet/diesel plant under development on a 125-acre former U.S. Army Ammunition production plant site in Riverbank, California. The blended sustainable aviation fuel is scheduled to begin deliveries to Qantas in 2025. "The use of sustainable aviation fuel by Qantas is another step toward lowering the environmental impact of aviation," stated Eric McAfee, Chairman and CEO of Aemetis. "Our supply of SAF to the San Francisco International Airport is supported by the California Low Carbon Fuel Standard, creating new investment and jobs in disadvantaged minority communities in the state."

08:21 EDT Datasea launches Ultrasonic Sound Sterilization, Antivirus Equipment - Datasea announced that it has launched the Ultrasonic Sound Sterilization and Antivirus Equipment targeting different application scenarios and planned to enter the US market with acoustic intelligence products. The company said, "The Ultrasonic Sound Sterilization and Antivirus Equipment features innovative acoustic intelligence powered disinfection that has proven to be able to purify air, reduce bacteria and viruses such as COVID-19 and H1N1 by over 99.9% through the research conducted by third-party laboratories. As sterilization and antivirus equipment combines ultrasonic sound effects with optics, it achieves high sterilization efficiency in normal temperature without human contact, peculiar odor, or environmental damage, and can respond to a wide range of disinfection needs. Datasea has prepared products targeting public and private application scenarios such as hospitals, airport, logistic warehouse, cold chain transportation and home care. Datasea's plan to enter the U.S. market is pursuant to the growth strategy and commitment to tap acoustic intelligence's full business potential. Based on the market potential analysis and product readiness, Datasea plans to introduce in U.S. the Ultrasonic Sound Sterilization and Antivirus Equipment and acoustic intelligence products in agriculture as the first step of the global footprint expansion. The acoustic intelligence products in agriculture utilize sound waves in the frequency range of 15-900Hz to carry out a large-scale harmless pest repellent and target rodents and insects, which is much needed by an agricultural giant like the United States."

08:19 EDT Gain Therapeutics presents data from its Parkinson's, Alzheimer's programs - Gain Therapeutics presented new pre-clinical data from its Parkinson's and Alzheimer's Disease programs. These results were highlighted in a poster presentation at the International Conference on Alzheimer's, AD, and Parkinson's Diseases, PD, being held March 15 - 20, 2022 virtually and in Barcelona, Spain. The data shows that improvement of the lysosomal function through the enhancement of glucocerebrosidase levels and activity can improve key pathological features in alpha-synucleinopathies and AD. "We are excited to present this data that provides further evidence of the significant therapeutic potential of our STAR small molecules in neurodegenerative diseases, including Parkinson's and Alzheimer's Disease," said Eric Richman, Chief Executive Officer of Gain. "It also continues to validate our computational target and drug discovery platform that is uniquely suited to identify novel allosteric binding sites and small molecule that regulate protein function." The presentation titled "Brain-penetrant Structurally targeted Allosteric Regulators for Glucocerebrosidase Show Promising Pharmacological Activity in Models of Parkinson Disease" demonstrated the following results: Orally bioavailable and brain-penetrant lead STARs reduce neurotoxicity derived from the accumulation of toxic oligomeric species of Abeta and alpha-synuclein; In the CBE-induced PD mouse model, treatment with the STAR small molecule resulted in: Decrease of CBE-induced neurotoxicity and motor deficit, Decrease of toxic forms of alpha-synuclein, Decrease of neuroinflammation. In an Abeta 1-42-induced AD neuronal model, treatment with the STAR small molecule resulted in: Decrease of Abeta 1-42-induced neurotoxicity, Decrease of hyperphosphorylated tau, Increase of neuronal survival, Improvement of the neurite network.

08:18 EDT BeiGene, Mediso announce Israel approval, reimbursements for BRUKINSA for WM - BeiGene and Medison Pharma announced that the State of Israel Ministry of Health has approved BRUKINSA zanubrutinib for the treatment of adult patients with Waldenstrom's Macroglobulinemia, WM. BRUKINSA is reimbursed nationally for patients with second- or third-line WM. This is the second approval for BRUKINSA in Israel, following its initial marketing and reimbursement approval in 2021 for patients with mantle cell lymphoma MCL who have received at least one prior therapy.

08:17 EDT BeiGene Mediso announce Israel approval, reimbursements for BRUKINSA for WM - BeiGene and Medison Pharma announced that the State of Israel Ministry of Health has approved BRUKINSA zanubrutinib for the treatment of adult patients with Waldenstrom's Macroglobulinemia, WM. BRUKINSA is reimbursed nationally for patients with second- or third-line WM. This is the second approval for BRUKINSA in Israel, following its initial marketing and reimbursement approval in 2021 for patients with mantle cell lymphoma MCL who have received at least one prior therapy.

08:16 EDT Enphase Energy acquires SolarLeadFactory - Enphase Energy announced the acquisition of SolarLeadFactory. Founded in 2012, the company provides high quality leads to solar installers. "For the past two years, we have executed on our installer digital platform strategy with the acquisitions of Sofdesk for solar design software, DIN's solar business for proposal and permitting services, 365 Pronto for O&M platform software, and now SolarLeadFactory for high-quality lead generation," said Badri Kothandaraman, president and CEO of Enphase Energy. "We chose the SolarLeadFactory team based on their high-quality mindset and operational efficiency. We are pleased to welcome the team and SolarLeadFactory's customers to Enphase."

08:14 EDT Constellium files annual report on Form 20-F - Constellium has filed its annual report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission.

08:13 EDT Reservoir Media announces publishing deal with Killer Mike - Reservoir Media announced a global publishing deal with Grammy-winning artist and songwriter Michael Render aka Killer Mike, who is part of the popular hip-hop super duo, Run The Jewels. The deal includes his entire catalog and future works. The Atlanta-born Mike has released four studio albums alongside his Run The Jewels partner, EL-P. Their most recent, RTJ4, soared to the Top 10 on the Billboard 200 and was met with widespread critical acclaim, landing at #1 on NME's The Best 50 Albums of 2020 list. Named the 2020 Spin Magazine Artist of the Year, Run The Jewels have won eleven Libera Awards, including the 2021 A2IM Humanitarian Award, took home four Clio Awards, including two Gold-winning Music Marketing campaigns, and received a 2018 Grammy nomination for Best Rap Song. The duo confirmed a tour with Rage Against The Machine, set for later this year.

08:13 EDT Philips announces latest Philips Capsule Surveillance receives FDA clearance - Royal Philips announced at HIMSS22 that the latest Philips Capsule Surveillance solution has received 510(k) market clearance from the U.S. Food & Drug Administration, paving the way for widespread deployment across healthcare systems in the USA. The solution aggregates patient data, analyses it to generate actionable insights and alerts, and sends timely notifications to the patient's caregivers so that they can intervene before deterioration progresses further. "This FDA clearance of the latest release of clinical surveillance solution enables more integrated viewing options within EMR and HIT tools through the secure web-based user interface. The updated intended use provides flexible deployment configurations that Philips Capsule can offer to hospitals and health systems in the USA," said Elad Benjamin, general manager of Clinical Data Services at Philips. "Properly implemented clinical surveillance has the potential to significantly improve patient outcomes by helping to avoid deterioration, while also improving the care team experience via clinical decision support and minimizing the burden of false and clinically unactionable alarms."

08:11 EDT Adtalem Global Education initiates $150M accelerated share repurchase program - Adtalem Global Education entered an accelerated share repurchase agreement with Morgan Stanley & Co. to repurchase $150M of the company's common stock. In addition to the $150M ASR program, the Adtalem board of directors also authorized open market share repurchases of up to $300M of the company's common stock over the next 36 months, both of which were previously announced on March 1.

08:10 EDT ATIF Holdings makes investment in iDea Electronics - ATIF Holdings announced it has made a strategic investment in iDea Electronics, a consumer technology innovator that delivers a broad range of consumer electronics and home environment products. ATIF now holds a 15% equity stake in iDea and is providing comprehensive IPO Advisory services to iDea as it prepares for an initial public offering in 2022. iDea Electronics has built strong recognition for its brand "iDeaPLAY."

08:09 EDT Blued reiterates commitment to online safety on World Consumer Rights Day - Blued is reiterating its commitment to ensuring the safety of its users this World Consumer Rights Day with a series of in-app features and operational efforts. By investing in cutting-edge technologies such as AI, Blued is ramping up its efforts in user privacy protection, anti-fraud, and user reporting, to ensure that its platform remains a safe and respectful environment. Protecting user privacy is central to Blued's mission. It prohibits users from taking a screenshot or recording a video while using the app. Users can choose to send ephemeral photos that disappear within seconds of being viewed, and they can also set their photo albums to private. Paid users have the option of replacing the Blued app icon with another image, as well as hiding their exact location in the "explore" page. To crack down on fraudulent accounts, Blued has formed a dedicated anti-fraud team that covers security, risk control, and technical AI identification. It developed a proprietary AI identification technology in 2021 that notifies users when there is a potential risk of fraud, while it sends in-app warnings when sensitive words are detected in private chats. Blued also carries out regular online safety campaigns to raise awareness on the issue. Blued has also improved its reporting mechanism by leveraging the latest in AI risk control and manual auditing. Users can report problematic behavior in the app's dedicated channel, which is then picked up by the 24/7 report handling team. This is to ensure that any issues are tackled with speed, so that users can enjoy the Blued experience.

08:08 EDT Vivint Smart Home names Ron Davies as company's first Chief Insurance Officer - Vivint Smart Home announced that Ron Davies has been named chief insurance officer. In this newly created role, Davies will lead all aspects of Vivint's growing smart insurance business, including the development of its market strategy, the company's development of its MGA with proprietary products, as well as its insurance agency. Davies will report to Vivint CEO, David Bywater.

08:07 EDT Alector presents AL001 data from the FTD-C9orf72 cohort of INFRONT-2 Phase 2 - Alector presented results from the INFRONT-2 Phase 2 clinical trial of AL001 in frontotemporal dementia patients, FTD, with a C9orf72 genetic mutation, FTD-C9orf72, at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders taking place virtually and in person in Barcelona, Spain. Latozinemab is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity and lysosomal health in the brain. FTD is a rare and rapidly progressing neurodegenerative disease that is the most common form of dementia for people under the age of 60. Today's data from the FTD-C9orf72 cohort build upon the results observed in the Company's studies to date in FTD-GRN patients. The results presented include 12-month data from up to 10 symptomatic FTD-C9orf72 patients treated with 60 mg/kg of latozinemab every four weeks in an open-label study designed to primarily assess the safety and tolerability of chronic dosing. The study also includes exploratory clinical outcomes assessments and biomarkers. Highlights from the presentation included the following observations: Latozinemab was generally well tolerated when administered monthly for a year or more; Latozinemab elevated progranulin in both plasma and cerebrospinal fluid in FTD-C9orf72 patients for the duration of treatment; Clinical outcome assessments using the CDR plus NACC FTLD-SB scale found that when compared to a matched control cohort from the ALLFTD consortium, treatment with latozinemab in FTD-C9orf72 patients resulted in a trend toward a delay of approximately 54 percent in annualized disease progression; Mean levels of neurofilament light chain, a marker of axonal damage, remained stable over the course of treatment in both plasma and CSF; Mean levels of glial fibrillary acidic protein, a biomarker of astrogliosis that is an indicator of disease and/or injury to the central nervous system, decreased over 12 months in both plasma and CSF.

08:07 EDT Pear Therapeutics announces data from studies evaluating PDTs for insomnia - Pear Therapeutics announced data that further underscore the effectiveness of Somryst, the only FDA-authorized PDT for the treatment of chronic insomnia. Results were presented in a symposia at World Sleep 2022, the international Congress of World Sleep Society, on March 15 in Rome, Italy. Interim data from the DREAM study, NCT04325464, a remote, virtual, open-label, decentralized clinical trial evaluating Somryst, analyzed in mid-Q1 2022, had 991 patients enrolled to date. In 779 patients who completed end-of-treatment , the population achieved statistically significant and clinically meaningful reductions in insomnia severity , sleep onset latency , and wake-after-sleep onset from baseline to post-treatment at nine weeks, and in the 193 patients who completed the 6 months follow-up, significant improvements in ISI, SOL, and WASO, were all maintained through six months.1 As part of its PearCreate platform, Pear has developed its own decentralized and fully virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which was used for the DREAM study. "These results provide strong evidence that older adults living with insomnia both use and obtain significant benefits from an interactive, remote program to treat their chronic insomnia, without needing special assistance," said Lee Ritterband, PhD, Professor and Director of the Center for Behavioral Health & Technology, University of Virginia School of Medicine in Charlottesville, Virginia. "These results demonstrate the value of remote interventions for chronic insomnia for older adults living with insomnia who may not otherwise have access to clinically validated treatment options like CBTi."

08:05 EDT Ready Capital's stockholders approve issuance of common stock - Ready Capital announced that at the special meeting of stockholders, conducted by means of a virtual meeting held live over the internet, its stockholders approved the issuance of the Company's common stock pursuant to the terms of the previously announced merger agreement pursuant to which Ready Capital has agreed to acquire via mergers a series of privately held, real estate structured finance opportunities funds with a focus on construction lending managed by MREC Management. Following the mergers, Ready Capital is expected to have a pro forma equity capital base in excess of $1.8B. The acquisition is expected to further expand Ready Capital's investment portfolio to include a diverse portfolio of construction assets with attractive portfolio yields resulting in expected earnings accretion and a reduced leverage profile. The Mergers are expected to close on March 16, 2022, subject to customary closing conditions. As a result of the Mergers, Ready Capital will acquire all of the outstanding equity interests in Mosaic Real Estate Credit, Mosaic Real Estate Credit TE, and MREC International Incentive Split, in exchange for an equal number of shares of each of Class B-1 Common Stock, $0.0001 par value per share, Class B-2 Common Stock, $0.0001 par value per share, Class B-3 Common Stock, $0.0001 par value per share, and Class B-4 Common Stock, $0.0001 par value per share, of Ready Capital, non-transferable contingent equity rights, or CERs, representing the potential right to receive additional shares of Common Stock as of the end of the three-year period following the closing of the Mergers based upon the performance of the assets acquired by Ready Capital pursuant to the Mergers, and cash consideration in lieu of any fractional shares of Class B Common Stock.

08:04 EDT Sabina Gold & Silver reports commencement of drilling at Goose Property - Sabina Gold & Silver Corp. is pleased to announce that drilling has commenced at the Goose Property on its 100%-owned Back River Gold Project in Nunavut, Canada. A planned 3,500-meter spring surface exploration drill program has started, with a focus on targeting the interface between the planned open pit and the down plunge zone at Umwelt. This drilling will allow for further characterization of the geology and mineralization of higher-grade gold zones in those areas which will inform optimization of the open pit and underground mine designs. Once complete, drilling will move to the Hook zone which is believed to be part of the gold structure linking the Goose Main and Nuvuyak gold deposits. Drilling is planned to be completed by mid April. "We look forward to receiving the results of this spring drilling program as we continue to evolve and develop the resource potential at the 8 km long Goose Gold Complex," said Bruce McLeod, President & CEO. "As we have demonstrated in past drilling campaigns, the gold endowment at Goose is exceptional and we remain committed to an exploration and resource growth and optimization strategy that we believe will add considerable value to the Project we progress towards production. With the application of our exploration framework through progressive 3D modeling, integrated data acquisition and drill testing, we are confident that we can continue to demonstrate the significant growth potential and world class nature of this well-endowed gold project."

08:04 EDT Local Bounti to acquire Pete's for $122.5M - Local Bounti announced that it has entered into a definitive agreement to acquire California-based complementary indoor farming company Hollandia Produce Group, which operates under the name Pete's, for total consideration of $122.5M, subject to customary adjustments. The Transaction consideration will be comprised of $92.5M in cash, expected to be provided pursuant to Local Bounti's existing lending facility with Cargill, and the remaining $30M of consideration payable in shares of Local Bounti common stock. It is anticipated that all of Pete's 130 employees will join Local Bounti for a combined total headcount of 250 employees. Pete's management team is expected to remain in place as the company becomes a wholly owned subsidiary of Local Bounti. The transaction is subject to customary closing conditions and a condition that the purchase of certain real estate owned by Pete's is completed. A Notification and Report under the Hart Scott Rodino Act was filed on January 18, and the waiting period expired on February 17. The Transaction is expected to close early second quarter.

08:03 EDT Schlumberger awarded integrated drilling contract from Saudi Aramco - Schlumberger announced a contract award by Saudi Aramco for integrated drilling and well construction services in a gas drilling project. The integrated project scope encompasses drilling rigs and technologies and services, including drill bits, measurement while drilling and logging while drilling, drilling fluids, cementing, and completing wells. Schlumberger will leverage digital solutions to enhance integrated drilling performance, including the DrillOps on-target well delivery solution which uses data analysis, learning systems and automation to execute a digital well plan, improving drilling efficiency, consistency and performance.

08:02 EDT AbbVie and Scripps Research announce global collaboration - AbbVie and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19. The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation. Closing of the transaction remains subject to satisfaction of customary closing conditions, including applicable regulatory approvals.

07:48 EDT Jacobs selected by the City of North Bay for PFAS cleanup at Garland Airport - Jacobs was selected by the City of North Bay, Ontario, for environmental assessment activities, development of a remedial design, and engineering consulting services related to per- and poly-fluoroalkyl substances, or PFAS, cleanup at the North Bay Jack Garland Airport. The airport lands are located atop the North Bay Escarpment and straddle a watershed divide between the Ottawa River to the east and the Great Lakes Basin to the west. Historically, aqueous firefighting foam, or AFFF, containing PFAS was used in firefighter training on the site. PFAS are chemically and biologically persistent and highly mobile in the environment.

07:43 EDT Idaho Strategic announces participation in IGEM Project - Idaho Strategic Resources is pleased to announce its partnership and participation in the Idaho Global Entrepreneurial Mission Project focused on the "Development of Idaho-Sourced Rare Earth Elements Drilling and Extraction". In addition to IDR, the complete list of participants includes the University of Idaho, Idaho Geological Survey, Idaho National Labs, Center for Advanced Energy Studies, and the Idaho Department of Commerce. The primary focus of the project is on environmentally friendly separation and processing techniques for neodymium, praseodymium, and yttrium. The overall goal of the IGEM Project is to advance Idaho-sourced rare earth elements, with a possible result being the demonstration of the potential for environmentally minded Idaho-based commercialization of REEs and REE end products. Idaho Strategic was chosen as the industry partner for the project due to its ownership of two nationally recognized REE project in Idaho. IDR plans to conduct roughly $1 million worth of rare earth element drilling on its Diamond Creek property near Salmon, Idaho, and will supply REE core samples to its program partners for study and analysis.

07:41 EDT Arrowhead files to start Phase 1/2a study of ARO-RAG for asthma treatment - Arrowhead Pharmaceuticals announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company's investigational RNA interference therapeutic designed to reduce production of the receptor for advanced glycation end products as a potential treatment for asthma and other inflammatory pulmonary diseases. James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: "ARO-RAGE is a new clinical candidate using the pulmonary targeted, inhaled TRiM platform. We believe RAGE is a promising target as it represents an upstream mediator of the inflammatory cascade in asthma. Importantly, a soluble form of RAGE known as sRAGE can be assessed as a useful serum biomarker to measure gene target knockdown. We hope to further investigate the potential of ARO-RAGE and our pulmonary platform broadly in the upcoming clinical study, including assessments of safety, pharmacokinetics, and target engagement in a non-invasive way. These insights can potentially help to inform the development path of future pulmonary candidates." An application for approval of the clinical trial was submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. Pending clearance, Arrowhead intends to proceed with ARORAGE-1001, a Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-RAGE in up to 64 healthy volunteers and in up to 16 patients with asthma.

07:39 EDT Coherus, Junshi announce presentation of results from CHOICE-01 trial - Shanghai Junshi Biosciences and Coherus BioSciences announced the presentation of positive results and biomarker analyses from the pivotal study "CHOICE-01," a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer, NSCLC. The final progression-free survival, PFS, analysis confirms the finding of the previous interim PFS analysis, demonstrating a statistically significant and clinically meaningful improvement in PFS per RECIST v1.1 compared to chemotherapy alone. The study also demonstrated an improvement in overall survival, OS, in a prespecified interim OS analysis. "In the CHOICE-01 study in patients with non-small cell lung cancer, toripalimab has once again demonstrated the potential to delay disease progression and help patients live longer," said Theresa LaVallee, PhD, Chief Development Officer at Coherus. "The study investigators also reported interesting biomarker data with toripalimab plus chemotherapy having activity independent of PD-L1 expression as well as a statistically significant overall survival advantage in NSCLC patients who have alterations in the focal adhesion-PI3K-AKT signaling pathway, a finding which may inform the design of future toripalimab clinical trials."

07:37 EDT Revival Gold provides exploration, development update - Revival Gold is pleased to provide the following exploration and development update for the Company's Beartrack-Arnett Gold Project located in Idaho, USA. A new mineral resource estimate for Beartrack-Arnett is expected by the end of April. Updated grade domains and economic parameters have been finalized. Block model and constrained resource estimation work by the Company's consultant, Wood, is in its final stages. Column leach test work in support of a Pre-Feasibility Study on the heap leach aspect of Beartrack-Arnett continues at SGS Lakefield with interim 60-day metallurgical results exhibiting recoveries generally in line with, or better than anticipated. Testing will continue for a minimum of 180 days. 2022 exploration plans have been finalized for a total of 7,000 meters of core and reverse circulation drilling at Beartrack-Arnett: Major Drilling has been contracted to commence 2,000 meters of core drilling, weather permitting, in May, in the Joss area to follow up drill hole BT21-240D which intersected 4.34 g/t gold over 110.6 meters including 12 g/t gold over 13.7 meters and 8.8 g/t gold over 11.8 meters in the final hole of last year's drill program. Drilling will focus on extending the dimensions of high-grade mineralization at Joss; An additional 2,000 meters of core drilling is planned in the Roman's Trench area and on the up-dip extension of mineralization in the Haidee area. At Roman's Trench, reverse circulation drilling in the 1990's intersected 1.90 g/t gold over 21 meters and 1.95 g/t gold over 18 meters in near-surface oxides. At Haidee, the up-dip oxide target is covered by a strong soil anomaly and represents a high priority opportunity to expand open pit mineralization in that location; and, 3,000 meters of reverse circulation drilling is planned for later this year to test several additional near surface oxide gold exploration opportunities. These are new targets for Revival Gold, each with well-developed soil and/or geophysical anomalies and/or elevated rock sampling results. Targets include the Midlands area, the Shenon Gulch area and a magnetic low that is similar in character to the magnetic low that underlies the mineral resource at Haidee. Ongoing engineering preparations for the PFS include geotechnical, geochemistry and hydrology studies, as well as mine planning and ore processing optimization trade off studies. Together with site environmental baseline data collection activities, the planned PFS is expected to provide sufficient project definition to develop project permitting documents necessary for the potential re-start of Beartrack-Arnett heap leach operations. The PFS is targeted for completion by year end. Meanwhile, Revival Gold has initiated a broader, property-wide evaluation of potential development concepts and processing alternatives, including potential high-grade, underground mining of transition and sulfide material.

07:35 EDT Zai Lab appoints Josh Smiley as COO - Zai Lab (ZLAB) announced the appointment of Josh Smiley as its COO. Smiley will report directly to Dr. Du and will be a key member of Zai Lab's executive committee. He will oversee all aspects of business, finance, and global operations. Mr. Smiley will be COO of Zai Lab beginning on August 1, 2022, following the completion of his leave with his current employer. Smiley began his career at Lilly (LLY) in 1995, holding leadership positions across the organization culminating in his most recent role of Senior Vice President and Chief Financial Officer. Mr. Smiley will relocate to the Boston area and be based in Zai Lab's office in Cambridge, Massachusetts.

07:34 EDT IBM to anchor SL Green's development at One Madison - SL Green Realty Corp. (SLG) announced that International Business Machines Corporation (IBM) has signed a 16-year, 328,000 square foot lease at One Madison Avenue covering portions of floors 2 and 7, entire floors 8 through 10 and a portion of the ground floor where IBM will have an exclusive lobby entrance creating a building within a building experience. This lease follows the recently announced 20-year, 56,000 square foot lease with Chelsea Piers Fitness. One Madison Avenue is SL Green's latest development scheduled for completion in November 2023.

07:33 EDT Kamada issues 2022 CEO letter to shareholders - Kamada issued the Letter to Shareholders from Amir London, Chief Executive Officer. "The recently completed 2021 year was a transformational period for Kamada in our path toward becoming a global leader in the plasma-derived specialty market... We are building on the strong foundation established over the years, entering 2022 as a "New Kamada" - a fully-integrated specialty plasma company with six FDA-approved products and strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries...The acquisition completed in November 2021, following a thorough search for the ideal assets for Kamada, was a critical strategic and synergistic step for the Company. The acquired products generated revenues exceeding $40 million in 2021, with over 50% gross margins...Of the four acquired products, the largest is Cytogam... The transition of Cytogam manufacturing to our facility is already well underway, and we expect to receive FDA approval for its production at our Israeli facility by early 2023...Another major strategic step taken is the acquisition of a plasma collection facility in Texas... We are already actively engaged in the expansion of the hyperimmune plasma collection capacity at this center and are simultaneously advancing our plan to open additional centers in the U.S. to further enhance our supply of specialty and regular plasma...During 2021, as planned, Takeda completed the transition of Glassia manufacturing to their own facility, and we fulfilled our supply commitments. Going forward, we expect to begin receiving royalty payments from Takeda, commencing during the second quarter of 2022, in the range of $10-$20 million per year from 2022 to 2040...Turning to our promising clinical development pipeline, we are excited about the potential of our innovative Inhaled AAT product for the treatment of AAT Deficiency... We are currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 study...As we enter 2022, the initial benefits of the decisive actions we have taken are already evident. Kamada is uniquely positioned for growth as a global leader in the specialty plasma industry, with multiple robust value-creating catalysts."

07:32 EDT RYAH secures medical device registration in New Zealand for Smart Inhaler system - RYAH Group announced that its subsidiary, RYAH Medtech, Inc., has received a medical device certification in New Zealand for its proprietary Internet of Things powered medical cannabis inhaler, proprietary cartridges and software application associated with the device. The certification comes in coordination with Medical Kiwi Ltd. as local sponsor for the New Zealand certification. Medical Device registration number 220314-WAND-6YNT17 from the New Zealand Medicines and Medical Devices Safety Authority allows RYAH to market its Smart Medical Inhaler System to medical patients in New Zealand and allows RYAH to immediately initiate a commercial strategy with Medical Kiwi to distribute the RYAH Smart Inhaler to patients in Medical Kiwi's network. The two companies previously announced that they entered into a formal supply and distribution agreement in New Zealand. This registration marks RYAH as one of the first medical devices for cannabis use to be approved in New Zealand and will provide critical anonymous session data to enable essential insights for plant-based therapies in the region.

07:25 EDT Anavex announces presentation of Phase 2 clinical data from ANAVEX 2-73-PDD-001 - Anavex Life Sciences announced the presentation of Phase 2 clinical biomarker data from the ANAVEX 2-73-PDD-001 Parkinson's Disease Dementia, PDD, study at AD/PD 2022 International Conference on Alzheimer's & Parkinson's Diseases and related neurological disorders, taking place in Barcelona, Spain, and virtually on March 15-20, 2022. The poster presentation titled, "ANAVEX2-73 - Analysis of Movement and Cognitiv Pharmacodynamic-Biomarker Outcome Measures of Placebo-Controlled Phase 2 Trial in 132 Parkinson's Disease Dementia Patients" is being presented by the Principal Investigator of the trial, Dr. Jaime Kulisevsky. MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with ANAVEX 2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant corresponding to a relative improvement of 18.9% over 14 weeks. Balanced and global improvements were observed within all MDS-UPDRS sub-scores Part I-IV. SIGMAR1 mRNA expression significantly increased in ANAVEX(R)2-73-treated patients vs placebo over the course of treatment and was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system. Christopher Missling, PhD, President & Chief Executive Officer of Anavex, remarked, "ANAVEX2-73 demonstrated dose-dependent efficacy for both motor impairment and cognition, which correlated with SIGMAR1 mRNA as a pharmacodynamic biomarker, respectively. These results support continued development of ANAVEX2-73 in Parkinson's disease and Parkinson's disease dementia as well as currently ongoing Precision Medicine biomarker-driven late-stage clinical studies in Rett syndrome and Alzheimer's disease. We would like to thank all the patients and participating families as well the investigators and clinical site coordinators for their dedication to this study."

07:22 EDT Enochian Biosciences, Caring Cross partner for CAR-T approach for HIV cure - Enochian BioSciences has issued an exclusive sub-license of one of its proprietary technologies that could improve the effectiveness of a potential cure for HIV with an anti-HIV CAR-T therapy that Caring Cross is studying in a clinical trial. Caring Cross is an innovative non-profit that partners with others, including for-profit companies, to increase access to new technologies and medicines under a collaborative value sharing model. Caring Cross and Enochian BioSciences entered into a profit-sharing agreement as part of the sub-license. The CAR-T approach being studied in humans was shown to cure HIV infection in an animal model that was published in the prestigious scientific journal, Science Translational Medicine. Based on those and other key data, Caring Cross received approval from the US Food and Drug Administration to advance to clinical studies that are being conducted by researchers from the University of California, San Francisco and the University of California, Davis with funding from the California Institute of Regenerative Medicine.

07:19 EDT Krystal Biotech enters binding term sheet for settlement with PeriphaGen - Krystal Biotech announced it has reached a binding term sheet with PeriphaGen to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020. Under the conditions of the term sheet, which are legally binding, Krystal will receive all of PeriphaGen's biological materials and skin assets and will pay PeriphaGen $25 million within 10 days of the completion of a Final Settlement Agreement. The parties are expected to enter into a final settlement agreement within 45 days of March 12, 2022. Upon approval of Krystal's first product by the U.S. Food and Drug Administration. Krystal will pay an additional $12.5 million, followed by three additional $12.5 million dollar milestone payments upon reaching $100 million in total cumulative sales, $200 million in total cumulative sales and $300 million in total cumulative sales reported by Krystal in its annual 10K filing. The settlement contains no admission of liability or wrongdoing and includes a full release of the claims made against Krystal Biotech, Inc., Krish Krishnan, Suma Krishnan, PeriphaGen, Inc., James Wechuck and David Krisky. Each party will bear their own costs and fees. The case is expected to be formally dismissed within a month.

07:18 EDT Plymouth Industrial REIT acquires 80% interest in Plymouth MIR JV for $102.6M - Plymouth Industrial REIT announced the acquisition of Madison International Realty's 80% interest in Plymouth MIR, the joint venture formed in December 2020 to acquire a portfolio of industrial buildings in metropolitan Memphis, Tennessee. The purchase included $46.6M in cash and closing costs in addition to the assumption of $56M in secured debt, which includes Plymouth's previous pro-rata share of a fixed-rate mortgage maturing in 2027 in the amount of $11.2M. The transaction is expected to provide a forward 12-month yield of 6.6% on the total consideration of $102.6M.

07:18 EDT Nuwellis announces IRB approval to begin REVERSE-HF clinical study - Nuwellis announced it has received independent Institutional Review Board approval for the trial protocol of the company's REVERSE-HF clinical study to evaluate the clinical outcomes and economic value of its Aquadex ultrafiltration therapy in comparison to intravenous diuretics for the treatment of fluid overload in patients with worsening heart failure. REVERSE-HF is a multicenter, open-label, randomized controlled trial that will be conducted across the United States. The study will be led by Sean Pinney, M.D., Professor of Medicine and Co-Director of the Heart and Vascular Center at The University of Chicago Medicine, and Maria V. DeVita, M.D., Professor of Medicine at Hofstra School of Medicine/Northwell and Chief of the Division of Nephrology at Lenox Hill Hospital. Enrollment in the trial will begin this year.

07:15 EDT Gran Colombia Gold reports Segovia February gold production 17,184 ounces - GCM Mining Corp. announced that its Segovia Operations produced 17,184 ounces of gold in February 2022, up from 15,360 ounces of gold in February last year. This brings the total gold production for the first two months of 2022 to 33,658 ounces, up from 30,415 ounces in the first two months last year. Segovia's trailing 12-months' total gold production at the end of February 2022 was 209,632 ounces, up about 1.6% over last year. GCM Mining processed a total of 48,512 tonnes in February 2022 at its Maria Dama plant at Segovia, representing a daily processing rate of 1,733 tonnes per day, compared with 42,345 tonnes and 1,512 tpd in February 2021. Segovia's head grades averaged 12.2 g/t in February 2022 compared with 12.5 g/t in February last year. For the first two months of 2022, a total of 90,527 tonnes were processed at Segovia at an average head grade of 12.8 g/t compared with a total of 83,771 tonnes at an average head grade of 12.6 g/t in the first two months last year. The Company continued to operate the new 200 tpd polymetallic plant at Segovia in test mode in February, processing an average of approximately 98 tpd of tailings resulting in the production of approximately 110 tonnes of zinc concentrate and approximately 86 tonnes of lead concentrate which have been stockpiled and are awaiting shipment once contractual agreements are finalized for the sale of the concentrates. Payable production from the concentrates in February 2022 is estimated to total approximately 91,000 pounds of zinc, 100,000 pounds of lead, 8,000 ounces of silver and less than 50 ounces of gold. Actual payable quantities are subject to change and will be finalized once the concentrates are shipped.

07:13 EDT Epizyme appoints Jerald Korn as COO - Epizyme (EPZM) announced the appointment of Jerald Korn as COO, reporting to president and CEO, Grant Bogle. Korn most recently served as the COO and general counsel at Kaleido Biosciences (KLDO), where he oversaw legal, human resources, program management, quality, regulatory and other operations, as well as supporting the company with corporate strategy, including two financings, a pipeline prioritization and transition to a new laboratory and manufacturing facility.

07:10 EDT Cogent Biosciences expects cash to fund operations into 2024 - As of December 31, 2021, Cogent had cash and cash equivalents of $219.7 million. The company believes that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2024.

07:09 EDT Veritone partners with EMPA GmbH on AI-enabled video discovery for Nurburgring - Veritone has announced a partnership with EMPA GmbH to work with SportTotal Live and ADAC Nordrhein e.V. to bring AI-enabled video discovery, metadata enrichment, and search capabilities to the 50th ADAC TotalEnergies 24h Race at the Nurburgring. The event on the circuit famously labeled the "Green Hell" to be held in Germany, May 26 to 29, is one of the largest international motor racing events and features an average of 180 cars and between 600 to 800 hobbyist and professional drivers.

07:05 EDT Imara sees cash, cash equivalents to fund operations through Q1 of 2023 - The Company currently expects that its full-year 2022 research and development expenses will range between $60M-$65M and that its full-year 2022 general and administrative expenses will range between $13M-$15M. Cash, cash equivalents and investments were $90.3 million as of December 31, 2021. The Company expects that its cash, cash equivalents and investments as of December 31, 2021, will be sufficient to enable it to fund its planned operations substantially through the first quarter of 2023.

07:04 EDT Main Street announces new portfolio investment - Main Street Capital announces that it recently completed a new portfolio investment to facilitate the majority recapitalization of Batjer & Associates and Batjer Service, a leading provider of mechanical HVAC and plumbing services for customers in the West Texas market. Main Street, along with its co-investor, partnered with the Company's existing owners and senior management team to facilitate the transaction, with Main Street funding $15.1M in a combination of first lien, senior secured term debt and a direct equity investment. In addition, Main Street and its co-investor are providing the Company with a revolving credit facility and delayed draw term loan to support its working capital needs and future growth initiatives.

07:03 EDT Passage Bio extends cash runway into 2Q24

07:02 EDT Cambridge Bancorp announces renewal of stock repurchase program - Cambridge Bancorp, the parent of Cambridge Trust Company, announced that on March 14 the Company's board of directors authorized the renewal of its stock repurchase program to acquire up to 5.0% of the total number of shares outstanding of the Company's common stock, with such purchases occurring prior to March 14, 2023. The timing and amount of any shares of the Company's common stock repurchased will be determined by the Company's management based on its evaluation of market conditions and other factors.

06:54 EDT Sanofi, Blackstone announces EUR 300M multiple myeloma collaboration - Sanofi (SNY) and Blackstone (BX) announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to EUR 300M to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma. If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022, the companies stated.

06:46 EDT Merck to stop Phase 3 KEYLYNK-010 trial - Merck announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. Merck is discontinuing the study following the recommendation of an independent Data Monitoring Committee after the DMC reviewed data from a planned interim analysis. At the interim analysis, the combination of KEYTRUDA and LYNPARZA did not demonstrate a benefit in overall survival, one of the study's dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide. The trial's other dual primary endpoint, radiographic progression free survival, was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. The safety profile of KEYTRUDA in combination with LYNPARZA in this trial was consistent with that observed in previously reported studies for the individual therapies; however, the combination was associated with a higher incidence of grade 3-5 adverse events and drug-related serious adverse events, compared to the control arm. Merck will inform study investigators of the recommendation from the DMC and advise patients in the study to speak to their physician regarding treatment. Data from this study will be presented at an upcoming scientific congress.

06:45 EDT Southwest continues to expect net loss in Q1, 'solidly profitable' in March

06:44 EDT Southwest sees FY22 capacity down 4% vs. 2019 - The company's flight schedule is currently published through September 5, 2022, and as previously disclosed, the company recently reduced its published flight schedules for March through May 2022 due to continuing challenges with available staffing. The company continues to estimate full year 2022 capacity to be down approximately four percent compared with 2019-approximately four points lower than the company's initial 2022 capacity plan communicated in December 2021.

06:42 EDT Southwest sees Q1 operating revenue down 8%-10% vs. 2019 - This compares to Southwest's previous view of down 10%-15%. Sees Q1 capacity down 9%-10% vs. 2019 vs. previous estimate of down about 9%. Sees Q1 CASM-X up 17%-12% vs. 2019 vs. previous view of up 20%-24%. Guidance provided in a regulatory filing.

06:38 EDT United Airlines continues to expect positive adjusted pre-tax income in Q2 - As a result of the strong revenue environment and based on a second quarter 2022 average fuel price per gallon of approximately $3.50, the Company continues to expect positive adjusted pre-tax income in second quarter 2022.

06:36 EDT Sage Therapeutics to present data from Phase 2 PARADIGM Study - Sage Therapeutics announced the presentation of data that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was associated with improvements on multiple tests of executive functioning and learning and memory in patients with mild cognitive impairment, or MCI, due to Parkinson's disease, or PD, in the open label Phase 2 PARADIGM Study. The PARADIGM Study is part of CogNEXT, Sage's early-stage trial platform designed to evaluate the therapeutic potential of SAGE-718 to treat cognitive deficits across a range of brain health disorders. The data were presented as a virtual oral presentation at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders taking place from March 15-20 both in-person in Barcelona, Spain, and virtually. In the PARADIGM Study, a comprehensive battery of tests was used to assess multiple domains of cognitive performance in eleven patients receiving SAGE-718 3 mg once daily.

06:34 EDT FTC Solar says long-term market outlook remains strong - Sean Hunkler, FTC Solar President and CEO, said "While 2021 was the perfect storm on cost pressures, we've taken significant actions, controlling what we can and focusing on advancing cost and margin improvements. The long-term market outlook remains strong, and I believe FTC Solar is uniquely positioned to continue to outpace the market in the U.S. while continuing to see accelerating growth internationally. FTC Solar offers a solution that is differentiated in the marketplace and is increasingly recognized by customers as a preferred choice. And we believe we're on the cusp of profitability with significant growth and margin improvement ahead. While we made good progress in 2021, I'm even more excited about where we'll go from here."

06:33 EDT United Airlines sees 2022 capacity down high single digits vs. 2019

06:32 EDT United Airlines says business recovery is accelerating - Sees very strong leisure demand across most of network. Says business traffic rebounding more quickly than expected. Says cargo performance continues to be unprecedented. Says MileagePlus redemption levels are strong and border restrictions are falling. Says bookings have trended up since the pandemic started, with smaller setbacks and business traffic has hit record levels since the start of the pandemic. Says business bookings are approximately 70% restored with business revenue close to 75% restored versus 2019. Comments taken from presentation slides for the JPMorgan Industrials Conference.

06:25 EDT Delta Air Lines plans to reduce adjusted net debt to $15B by 2024

06:24 EDT Delta Air Lines sees March quarter capacity ~83% vs. 83%-85% initial view

06:22 EDT Delta Air Lines raising March quarter revenue outlook to ~78% recovered vs. 2019 - Says system cash sales above 2019 levels.

06:19 EDT Dole sees FY22 CapEx $125M - Sees FY22: Net Interest Expense of approximately $45M; Effective tax rate in the range of 25.0%-28.0%.

06:07 EDT China Yuchai incorporates joint venture subsidiary - China Yuchai announced the joint venture, Beijing Yuchai Xingshunda New Energy Technology, between its subsidiary Yuchai Xin-Lan New Energy Power Technology and Beijing Xing Shun Da Bus, has been incorporated in the Daxing District, Beijing, China with registered capital of RMB 10M. As announced on October 20, 2021, the joint venture will combine the resources of both partners to accelerate the development, manufacturing and sale of fuel cell powertrain systems as well as core fuel cell power system components for the Beijing, Tianjin and Hebei markets.

06:05 EDT Matrix PDM awarded contract to expand natural gas processing facility - Matrix Service Company announced that an industry leading company in the natural gas value chain has awarded Matrix PDM the engineering, procurement, and construction of the expansion of a natural gas processing facility to double existing facility capacity.

06:02 EDT CareTrust REIT raises quarterly dividend to 27.5c from 26.5c per share - The current dividend will be payable to common stockholders of record as of the close of business on March 31, and management affirmed that the company plans to pay the dividend on or about April 15.

05:29 EDT National Instruments announces opening of EIC in Bangalore - NI announced the opening of its Engineering Innovation Centre, or EIC, in Bangalore. The engineering lab, which opened late 2021, supports NI's customers, partners and startup companies that serve the local aerospace and defense market. The EIC will also be used to train the next generation of engineers who need systems knowledge in the aerospace and defense industry.

05:24 EDT CooTek chairman, CTO Karl Kan Zhang to purchase up to $3M in ADS - CooTek announced that Karl Kan Zhang, CooTek's chairman of the board of directors and CTO has informed the company of his intention to use his personal funds to purchase up to $3M of the company's American Depositary Shares, or ADS, for the next six months, pursuant and subject to applicable laws and the company's securities trading policy. Zhang has agreed to be subject to lock-up restrictions for a period of at least six months with respect to the proposed purchased ADSs.

05:16 EDT Illumina launches TruSight Oncology Comprehensive genomic profiling test - Illumina announced the launch of TruSight Oncology, or TSO, Comprehensive, a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic kit will help inform precision medicine decisions for cancer patients across the continent.